Stock Ratings / Health Care / BOLT / dividends

RKTO (40) LPCN (23) KTTA (40) HIND (29) ⌘ Pro Terminal →

Bolt Biotherapeutics Inc. (BOLT) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.59 +3.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.62

Bolt Biotherapeutics Inc. (BOLT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $12.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BOLT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.59 (+3.62% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #593 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BOLT compare to RKTO and LPCN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RKTO (Rocket One Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M) and LPCN (Lipocine Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BOLT?

▼

Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.62 (+0.46%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY BOLT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (37% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 75% of 52W Range • RSI-14 at 72.4 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.28+0.7% Next Q

Q2 (-2Q)

Grade E$4.31+47.8% Next Q

Q3 (-1Q)

Grade E$6.37+3.5% Next Q

Current

Grade D-$6.59-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BOLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BOLT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($6.92) forces dealer call-delta covering toward $8.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BOLT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLT)

✓Walkthrough of BOLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BOLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.24%📐 HORIZONTAL RANGE

2026-11-03O $6.36H $6.59L $6.36C $6.59VOL 249.9K

RES: $7.92SUP: $3.06SMA50: $4.25SMA200: $4.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BOLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BOLT Butterfly Map → + Track BOLT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BOLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BOLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BOLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLT)

Health Care Rank #593 of 1016 ⚔️ RKTO vs BOLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BOLT vs. RKTO, LPCN, KTTA, HIND)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bolt Biotherapeutics Inc. (BOLT) ranks #593 by composite RQD confidence (38/100, grade D-) and #877 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, BOLT leads on earnings valuation at N/A trailing P/E, while BOLT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with BOLT at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BOLT ACTIVE Bolt Biotherapeutics Inc.	D-	38/100	—	—	-35.0%	+3.62%	$12.7M	Benchmark Subject
RKTO Rocket One Inc.	D-	40/100	—	—	-35.0%	-5.60%	$12.8M	/rkto-vs-bolt →
LPCN Lipocine Inc.	E	23/100	—	—	-35.0%	-5.26%	$12.5M	/lpcn-vs-bolt →
KTTA Pasithea Therapeutics Corp.	D-	40/100	—	—	-35.0%	+0.16%	$12.3M	/ktta-vs-bolt →
HIND Vyome Holdings Inc.	E	29/100	—	68.4%	-35.0%	+2.86%	$12.3M	/hind-vs-bolt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001641281

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported GAAP revenue of $7.7M (+0.1% vs. FY2024 revenue of $7.7M , and -2.3% cumulative change since FY2023) , GAAP net income of -$33.4M, operating cash flow of -$39.9M, and free cash flow of -$39.9M (+34.9% YoY). On the balance sheet, BOLT closed FY2025 with $56.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.7M	-$33.4M	-$39.9M	-$39.9M	$56.7M	—
FY2024 (FY)	2024-12-31	$7.7M	-$63.1M	-$61.3M	-$61.3M	$99.6M	—
FY2023 (FY)	2023-12-31	$7.9M	-$69.2M	-$69.5M	-$69.5M	—	—

3. BOLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BOLT compare to RKTO and LPCN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BOLT?

Where is BOLT trading relative to its 50-day, 200-day, and 52-week technical levels?

BOLT last traded at $6.59 (+3.62% on volume of 249,919 shares), positioning the stock +55.06% above its 50-day simple moving average ($4.25) and +46.12% above its 200-day simple moving average ($4.51). Across its 52-week range of $3.10 to $7.78, BOLT sits at the 74.6% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.77 to $7.41).

BOLT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BOLT pay a dividend and is it safe?

Bolt Biotherapeutics Inc. (BOLT) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BOLT RQD Cockpit BOLT 12M Forecast BOLT Earnings & Move BOLT Dividends & DRIP BOLT Insiders & 13F BOLT Whale Options BOLT Profit Sankey BOLT News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BOLT — Bolt Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BOLT scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 4 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For an investor, this indicates the business is not currently generating returns on capital or free cash flow, so value must rest on future outcomes rather than present earnings power.
Whale 13F Flow: 14 / 20. Described as institutional accumulation and options positioning. This is the strongest pillar, suggesting some institutional interest, though the rating does not disclose the magnitude or direction of specific holdings.
Insider Conviction: 3 / 20. Based on SEC Form 4 and Congressional PTR cluster flow. A low score here means insider activity provides little supporting conviction signal.
Macro Regime Fit: 9 / 20. Beta of 1.0 with sector sensitivity noted. The stock's market sensitivity is neutral, but the score reflects limited alignment with the prevailing regime.
Forensic Balance Sheet: 8 / 20. Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. These point to elevated financial fragility and weak fundamental quality signals.

Taken together, the rating frames BOLT as a speculative, cash-consuming company whose equity value is highly dependent on near-term financing and clinical or strategic outcomes. The score does not imply a precise price target; it reflects a weak composite profile across fundamentals, balance sheet, and insider signals, partially offset by institutional interest.

Business

Bolt Biotherapeutics Inc. (BOLT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is a publicly traded biotechnology business. Source data does not specify its products, customers, or revenue model. Per the SEC financials, reported revenue was $7.7M for FY 2025 and $7.7M for FY 2024. Per recent news, the company announced an acquisition of Prana Therapies alongside a $120 Million concurrent private placement to advance PRA-216 in inflammatory indications.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$7.7M	$-36.1M	$-33.4M	N/A	$-39.9M	$11.7M	N/A
FY 2024	$7.7M	$-73.0M	$-63.1M	N/A	$-61.3M	$7.2M	N/A
FY 2023	$7.9M	$-76.2M	$-69.2M	N/A	$-69.5M	N/A	N/A

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported operating losses and negative free cash flow persisted across the three periods shown. Reported cash rose to $11.7M in FY 2025 from $7.2M in FY 2024, while debt is not available in source data.

Recent Catalysts & News Wire Analysis

Primary catalyst (per the news wire): Multiple outlets, including Fierce Biotech, Yahoo Finance, The Pharma Letter, marketscreener.com, and citybiz, report the Prana Therapies acquisition and a $120 Million financing. One marketscreener.com item references expected funding of $119.999995 million.
Market reaction: An Investorideas.com item reports the stock "soars on acquisition news," and one item is tagged as a green-light catalyst. Current price of 6.36 reflects a -3.34% change per the market data.
Risk watch items: Most items are tagged as yellow-light market wire, signaling mixed or unconfirmed signal strength. The financing is a concurrent private placement, which may imply dilution; source data does not quantify share issuance.
Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are recorded.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that the acquisition of Prana Therapies and the PRA-216 program are the only identifiable ripple pathways in the news, and their operational interdependencies are not specified in source data.

Open Questions

What are the specific terms, share count, and dilution impact of the $120 Million concurrent private placement?
What is the status and stage of PRA-216, and what clinical or commercial milestones are associated with the Prana acquisition?
What is BOLT's debt position, given debt is listed as N/A across all periods?
Why does reported revenue hold flat at $7.7M across FY 2025 and FY 2024, and what drives it?
What is the source and composition of the 14/20 institutional 13F flow, including the identity and size of major holders?

BOLT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bolt Biotherapeutics Inc. (BOLT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BOLT Debate Forum (3) ↓

🟡 MARKET WIRE Fierce Biotech • 15h ago

Bolt makes inflammation play with Prana reverse merger, $120M financing

Fierce Biotech report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 18h ago

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Yahoo Finance report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investorideas.com • 21h ago

Biotech Stock Bolt Biotherapeutics (Nasdaq: BOLT) Soars on Acquisition News

Investorideas.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Pharma Letter • 1d ago

Bolt Biotherapeutics acquires Prana Therapies

The Pharma Letter report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 1d ago

Bolt Biotherapeutics, Inc. announced that it expects to receive $119.999995 million in funding from a group of investors

marketscreener.com report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE citybiz • 1d ago

Bolt Biotherapeutics Acquires Prana Therapies, Secures $120 Million Financing to Advance Clinical Pipeline

citybiz report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Bolt Biotherapeutics Completes Prana Merger Alongside $120 Million Financing

TradingView report covering Bolt Biotherapeutics Inc. (BOLT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BOLT Bull vs. Bear Conversation Board — What's Your Call at $6.59?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BOLT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.60 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BOLT (D- • RQD 38/100) a Buy at $6.36?

Welcome to the BOLT (Bolt Biotherapeutics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.77 (-25.0%)

Spot @ $6.36

Pump the brakes on BOLT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BOLT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Bolt Biotherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.82 (+23.0%)

Spot @ $6.36

BOLT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BOLT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.36 (52-wk range $3.10 - $7.78), any beat on forward guidance forces shorts and underweight funds to chase.